Hemostasis Today

July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk
May 29, 2026, 09:52

Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk

Sergio Emanuel Kaiser, Coordinator at UERJ – Discipline of Clinical and Experimental Pathophysiology, Associate Professor of Medicine at Rio de Janeiro State University, shared a post on LinkedIn about a recent article by Kausik Ray, published in JACC, adding:

“EAS Congress 2026.

A new actionable pathway is tested in a phase 1 study by Kausik Ray and collaborators.

Rivonoplast, a potent inhibitor of NLRP3 inflamassome led to early and sustained reversible sCRP reduction compared to placebo.

Some pictures from his presentation depicted below.”

Title: Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk

Authors: Kausik K. Ray, Nicholas Clarke, Peter Thornton, Amy E. Miles, Zsofia Digby, Melanie J. Davies, Michelle Gorman, Bianca Mullen, Valérie Reader, Missy Magill, Hilary Johnstone, Cono Ariti, Naveed Sattar, Nikolaus Marx, Ann Marie Navar, Adrian F. Hernandez, Jyothis T. George, Alan P. Watt, Javed Butler, Paul M. Ridker

Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk

Stay updated on all scientific advances with Hemostasis Today.